"I hadn't completely dismissed the possibility that there  could be adverse side effects....but I was thinking that any such safety concerns and/or side effects, that it might take longer...say if we get approval and people were to take Apabetalone for say 5 or 10 years."

How apropos to this discussion of long-term safety that the SGLT2 inhibs just got some bad press yesterday for increased risk of "Flesh-Eating Genital Infection." Also pointed out by JK over on Stockhouse. I'm not saying that this SGLT2 inhib risk has anything to do with apabetalone. Just using SGLT2i as example to point out that sometimes adverse events observations don't pop up prior to drug approval. It was already known that some, if not all, SGLT2 inhibs have increased risk of urinary tract and yeast infections. But Flesh-Eating Genital Infection is quite alarming to see in a headline!

BDAZ